Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL...
42 insider purchases on record · latest filing 2025-12-10.
Insiders have also filed 2 sale transactions at IMMX.